Gastrointestinal Implications of Voriconazole Exposure

Withdrawn before enrolling

Conditions studied: Infection

In brief

Voriconazole has better response rates, improved survival and less adverse side effects compared to other drugs for the treatment of invasive fungal infections making it a desirable therapeutic option for children. However, dosing is unpredictable in children and this leads to therapeutic failure. This study aims to understand the physiological differences between children and adults that leads to therapeutic failure of voriconazole in children.

Key facts

Study ID
NCT02904434
Run by
Children's Hospital of Philadelphia
People needed
0
Starts
2016-09-01
Expected to finish
2020-06-01
Last updated by the study team
2020-04-09

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.